Xenon Pharmaceuticals Inc.

Historical 13F Holders

Symbol
XENE
CUSIP
98420N105
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 98420N105 since 12/18/2024, newest first.

Filer % of Class Filed
Wellington Management Group LLP 13G/A Amendment 1
1.5% 8/13/2026
Event 6/30/2026
FMR LLC 13G/A Amendment 8
10.3% 8/7/2026
Event 7/31/2026
FMR LLC 13G/A Amendment 7
9.9% 8/6/2026
Event 6/30/2026
Janus Henderson Group PLC 13G/A Amendment 1 4.5% 5/15/2026
Event 3/31/2026
Driehaus Capital Management LLC 13G/A Amendment 3 4.9% 5/15/2026
Event 12/31/2025
Avoro Capital Advisors LLC 13G/A Amendment 5
6.3% 5/15/2026
Event 3/31/2026
Wellington Management Group LLP 13G
6.2% 2/10/2026
Event 12/31/2025
Janus Henderson Group PLC 13G 5.1% 11/14/2025
Event 9/30/2025
Wellington Management Group LLP 13G/A Amendment 1
2.8% 8/12/2025
Event 6/30/2025
FMR LLC 13G/A Amendment 6
11.5% 8/6/2025
Event 6/30/2025
BlackRock, Inc. 13G 6.2% 7/17/2025
Event 6/30/2025
FMR LLC 13G/A Amendment 5
10.3% 3/7/2025
Event 2/28/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 5 12.2 k $443 k
2026 Q2 325 107 M $6.19 B
2026 Q1 310 100 M $5.81 B
2025 Q4 266 84.6 M $3.79 B
2025 Q3 235 86.3 M $3.46 B
2025 Q2 218 83.4 M $2.61 B
2025 Q1 218 76.8 M $2.58 B
2024 Q4 217 76.3 M $2.99 B
2024 Q3 214 75.9 M $2.99 B
2024 Q2 229 75.2 M $2.93 B
2024 Q1 234 75.2 M $3.24 B
2023 Q4 230 73.6 M $3.39 B
2023 Q3 201 62.5 M $2.14 B
2023 Q2 188 63.3 M $2.44 B
2023 Q1 174 62.9 M $2.26 B
2022 Q4 170 62.8 M $2.48 B
2022 Q3 162 58.4 M $2.11 B
2022 Q2 158 57.2 M $1.74 B
2022 Q1 143 49.4 M $1.51 B
2021 Q4 141 50.1 M $1.57 B
2021 Q3 140 34.1 M $522 M
2021 Q2 111 35.3 M $703 M
2021 Q1 95 33.5 M $599 M
2020 Q4 82 28.0 M $431 M
2020 Q3 82 27.9 M $309 M
2020 Q2 81 28.0 M $351 M
2020 Q1 71 27.7 M $314 M
2019 Q4 69 18.7 M $245 M
2019 Q3 54 16.1 M $145 M
2019 Q2 60 17.6 M $173 M
2019 Q1 63 17.7 M $180 M
2018 Q4 60 17.5 M $110 M
2018 Q3 62 17.7 M $235 M
2018 Q2 43 9.24 M $84.7 M
2018 Q1 35 6.35 M $31.1 M
2017 Q4 32 9.16 M $25.9 M
2017 Q3 31 9.32 M $27.5 M
2017 Q2 39 9.95 M $31.3 M
2017 Q1 39 10.1 M $40.3 M
2016 Q4 32 10.5 M $80.8 M
2016 Q3 31 9.94 M $80.6 M
2016 Q2 22 5.38 M $32.0 M
2016 Q1 25 5.71 M $39.9 M
2015 Q4 26 5.84 M $47.0 M
2015 Q3 26 5.68 M $46.9 M
2015 Q2 26 4.81 M $55.4 M
2015 Q1 23 4.45 M $75.2 M
2014 Q4 17 4.28 M $83.1 M